Abstract

To determine whether a low-dose intravenous insulin regimen reduces blood glucose levels at a timely rate and associated side effects among patients with Acute Coronary Syndrome and Left Ventricular Failure. Induced hypoglycaemia and the associated risks have questioned the benefits of intensive insulin therapy in patients presenting with raised blood glucose levels and Acute Coronary Syndromes. Local audit data identified that patients with Acute Coronary Syndrome and Left Ventricular Failure experienced more hypoglycaemic episodes than those with Acute Coronary Syndrome alone. Consequently, a new regimen of low-dose insulin for this group was implemented and audited over 12months. Audit. Thirty-six consecutive patient notes with a diagnosis of Acute Coronary Syndrome and blood glucose of ≥10mmol/l treated with a new insulin therapy regimen were analysed. Data were extracted using a standardised form and entered into an Excel spreadsheet for analysis. The mean age of the sample was 70years with 66% of subjects being men and 50% presenting with Acute Coronary Syndrome and Left Ventricular Failure. The low-dose regimen was effective in achieving normoglycaemia, (range 4-8mmol/l) for a consecutive six-hour period. This was achieved in 72% of patients and within a median time of 13hours. The audit suggests that a low-dose insulin regimen can effectively stabilise blood glucose in patients presenting with both Acute Coronary Syndrome and Left Ventricular Failure. The importance of regularly monitoring blood sugar levels is vital and highlights the role of nurses in minimising patient risk and promoting safety. Nurses are instrumental in the safe implementation of intensive insulin guidelines. Close monitoring of patients is essential, enabling timely adjustments to treatments and ensuring patient safety. Regular audits allow nurses to evaluate care provision and continue to drive practice forward.

Highlights

  • Contradictory findings (National Institute for Health and Clinical Excellence (NICE) 2013, Ryden et al 2013) relating to the benefits of intensive insulin therapy for individuals presenting with Acute Coronary Syndromes (ACS) and hyperglycaemia has resulted in a lack of clear guidance for optimising management of these patients

  • The publication of conflicting evidence has questioned the clinical value of intensive insulin therapy in the management of ACS patients presenting with hyperglycaemia

  • When managing hyperglycaemia in ACS patients numerous strategies are available and the debate as to which is best will continue until definitive trial data becomes available

Read more

Summary

Introduction

Contradictory findings (National Institute for Health and Clinical Excellence (NICE) 2013, Ryden et al 2013) relating to the benefits of intensive insulin therapy (an intravenous infusion of insulin and glucose with or without potassium) for individuals presenting with Acute Coronary Syndromes (ACS) and hyperglycaemia has resulted in a lack of clear guidance for optimising management of these patients. Hypoglycaemia is considered a serious side effect of intensive insulin therapy with evidence linking hypoglycaemia to adverse outcomes in ACS patients. The authors concluded that an increased mortality risk is confined to patients developing hypoglycaemia spontaneously and not as a result of insulin therapy. The publication of conflicting evidence has questioned the clinical value of intensive insulin therapy in the management of ACS patients presenting with hyperglycaemia

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call